Pharmacoeconomic aspects of using enzalutamide for treatment of patients with nonmetastatic castration-resistant prostate cancer
Background. Prostate cancer is one of the most common malignant diseases among men. Until recently, the most common treatment of nonmetastatic castration-resistant prostate cancer (nmCRPC) in Russia was to continue previously started hormonal therapy. Enzalutamide is a second-generation anti-androge...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2020-07-01
|
| Series: | Onkourologiâ |
| Subjects: | |
| Online Access: | https://oncourology.abvpress.ru/oncur/article/view/1344 |